J. Goldman & Co LP Makes New Investment in Geron Corporation $GERN

J. Goldman & Co LP purchased a new stake in shares of Geron Corporation (NASDAQ:GERN) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 712,124 shares of the biopharmaceutical company’s stock, valued at approximately $912,000. J. Goldman & Co LP owned 0.11% of Geron as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. RA Capital Management L.P. grew its position in shares of Geron by 5.6% during the fourth quarter. RA Capital Management L.P. now owns 63,771,366 shares of the biopharmaceutical company’s stock worth $84,178,000 after purchasing an additional 3,392,000 shares in the last quarter. BlackRock Inc. bought a new stake in Geron during the 2nd quarter valued at approximately $62,868,000. Vanguard Group Inc. lifted its holdings in Geron by 3.6% in the 4th quarter. Vanguard Group Inc. now owns 35,660,969 shares of the biopharmaceutical company’s stock worth $47,072,000 after purchasing an additional 1,237,844 shares in the last quarter. State Street Corp lifted its holdings in Geron by 0.9% in the 4th quarter. State Street Corp now owns 26,867,322 shares of the biopharmaceutical company’s stock worth $35,465,000 after purchasing an additional 248,508 shares in the last quarter. Finally, Vestal Point Capital LP boosted its stake in Geron by 8.0% in the 2nd quarter. Vestal Point Capital LP now owns 23,775,000 shares of the biopharmaceutical company’s stock worth $33,523,000 after purchasing an additional 1,769,660 shares during the period. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $4.00.

Geron Stock Down 1.3%

Shares of GERN stock opened at $1.53 on Thursday. The company’s fifty day simple moving average is $1.44 and its two-hundred day simple moving average is $1.48. Geron Corporation has a 52 week low of $1.04 and a 52 week high of $2.01. The stock has a market cap of $982.98 million, a P/E ratio of -13.91 and a beta of 0.61. The company has a quick ratio of 5.16, a current ratio of 6.91 and a debt-to-equity ratio of 0.55.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Geron had a negative net margin of 34.17% and a negative return on equity of 24.48%. The firm had revenue of $57.48 million for the quarter, compared to analysts’ expectations of $55.30 million. Analysts predict that Geron Corporation will post -0.04 EPS for the current fiscal year.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.